Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mefloquine
Drug ID BADD_D01369
Description Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.[L30618] Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin.[L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.[A226838] This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Indications and Usage Mefloquine is indicated for the treatment of mild to moderate cases of malaria caused by Plasmodium falciparum and Plasmodium vivax. It is effective against chloroquine-resistant forms of Plasmodium falciparum. Mefloquine is also indicated for the prophylaxis of malaria caused by Plasmodium falciparum and Plasmodium vivax, including chloroquine-resistant forms of Plasmodium falciparum.[L8953]
Marketing Status approved; investigational
ATC Code P01BC02
DrugBank ID DB00358
KEGG ID D04895
MeSH ID D015767
PubChem ID 4046
TTD Drug ID D0GQ7K
NDC Product Code Not Available
UNII TML814419R
Synonyms Mefloquine | Mephloquine | WR-177,602 | WR 177,602 | WR177,602 | Ro-21-5998-001 | Ro 21 5998 001 | Ro215998001 | WR-142,490 | WR 142,490 | WR142,490 | Lariam | Mefloquine Hydrochloride
Chemical Information
Molecular Formula C17H16F6N2O
CAS Registry Number 49752-90-1
SMILES C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams17.15.02.001; 19.02.03.001---
Aggression19.05.01.001---
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Alopecia23.02.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anger19.04.02.001---
Antisocial behaviour19.05.01.010---
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002---
Arthralgia15.01.02.001--
Arthropod bite12.01.08.022---
Asthenia08.01.01.001---
Ataxia08.01.02.004; 17.02.02.001--
Atrioventricular block02.03.01.002---
Blister12.01.06.002; 23.03.01.001---
Body temperature increased13.15.01.001---
Bradycardia02.03.02.002---
Breast feeding26.05.01.001---
Cardio-respiratory arrest02.03.04.002; 22.02.06.007---
Cardiovascular disorder02.11.01.010; 24.03.02.009---
Cataract06.06.01.001--
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Chills08.01.09.001; 15.05.03.016--
Coma17.02.09.001---
Completed suicide08.04.01.010; 19.12.01.001---
Conduction disorder02.03.01.008--
Confusional state17.02.03.005; 19.13.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene